Anzeige
Mehr »
Login
Donnerstag, 28.03.2024 Börsentäglich über 12.000 News von 687 internationalen Medien
Spezial am Donnerstag: Rallye II. - Neuer Anstoß, News und was die Börsencommunity jetzt nicht verpassen will…
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PLR5 | ISIN: US00650F1093 | Ticker-Symbol: 1HM
Tradegate
28.03.24
12:12 Uhr
2,782 Euro
+0,099
+3,69 %
1-Jahres-Chart
ADAPTIVE BIOTECHNOLOGIES CORPORATION Chart 1 Jahr
5-Tage-Chart
ADAPTIVE BIOTECHNOLOGIES CORPORATION 5-Tage-Chart
RealtimeGeldBriefZeit
2,7342,79312:57
2,7342,79312:56

Aktuelle News zur ADAPTIVE BIOTECHNOLOGIES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
29.02.Adaptive Biotechnologies Corp - 10-K, Annual Report5
22.02.Adaptive Biotechnologies to Present at the TD Cowen 44th Annual Healthcare Conference2
15.02.Adaptive Biotechnologies Corp reports results for the quarter ended in December - Earnings Summary5
14.02.Adaptive Biotechnologies GAAP EPS of -$0.48 misses by $0.15, revenue of $45.78M misses by $2.68M3
14.02.Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results139SEATTLE, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation ("Adaptive Biotechnologies") (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics...
► Artikel lesen
13.02.Adaptive Biotechnologies Q4 2023 Earnings Preview6
13.02.Earnings Preview For Adaptive Biotechnologies4
29.01.Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2023 Financial Results on February 14, 20245
27.12.23Adaptive Biotechnologies to Present at the 42nd Annual J.P. Morgan Healthcare Conference2
09.12.23Adaptive Biotechnologies Announces New Data Highlighting the Clinical Relevance of MRD Testing with clonoSEQ in Patients with Blood Cancers at the 65th ASH Annual Meeting168Treatment adapted studies show the potential for MRD assessment to guide the personalization of blood cancer careNew data demonstrates MRD assessed from blood in multiple myeloma may be an indicator...
► Artikel lesen
05.12.23Adaptive Biotechnologies and Collaborators to Present More than 30 Abstracts Demonstrating the Actionability of clonoSEQ® MRD Testing in Blood Cancer Patient Care and Drug Development at the 65th ASH Annual Meeting4
10.11.23Biolase, Adaptive Biotechnologies among healthcare movers12
10.11.23Earnings call: Adaptive Biotechnologies Q3 2023 report reveals strategic review and revenue decline7
10.11.23Adaptive Biotechnologies Corp reports results for the quarter ended in September - Earnings Summary8
09.11.23Adaptive Biotechnologies GAAP EPS of -$0.35 misses by $0.01, revenue of $37.92M misses by $5.04M4
09.11.23Recap: Adaptive Biotechnologies Q3 Earnings1
09.11.23Adaptive Biotechnologies Corp - 8-K, Current Report1
09.11.23Adaptive Biotechnologies Reports Third Quarter 2023 Financial Results and Provides Business Update156SEATTLE, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation ("Adaptive Biotechnologies") (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics...
► Artikel lesen
07.11.23Adaptive Biotechnologies Announces New Translational Collaboration to Measure Minimal Residual Disease with clonoSEQ® Assay Across BeiGene's Lymphoid Malignancy Pipeline2
02.08.23Adaptive Biotechnologies Reports Second Quarter 2023 Financial Results399SEATTLE, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation ("Adaptive Biotechnologies") (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics...
► Artikel lesen
Seite:  Weiter >>
23 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1